New HIV vaccine trial aims to boost immune control in patients on ART
NCT ID NCT07530198
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental HIV vaccine called ICVAX in 22 adults with HIV who are stable on antiretroviral therapy (ART). The goal is to see if the vaccine is safe and can strengthen the body's immune response against HIV. Participants receive four injections over several months and are monitored for about a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Chinese University of Hong Kong Phase 1 Clinical Trial Centre at Prince of Wales Hospital
RECRUITINGShatin, New Territories, 00000, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking groups could shield HIV-Positive latino men from heart disease
- Friends helping friends: a novel social-network strategy to boost HIV prevention
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
- Could HIV and age weaken vaccine protection? study investigates
- Massive HIV database could unlock secrets of Long-Term health
- Can couples counseling curb HIV? new study tests dyadic approach in south africa